Search

This study describes the distribution of glycosylated haemoglobin (HbA1c) and glucose concentrations in the combined year 1 (2008-2009), year 2 (2009-2010) and year 3 (2010-2011) of the National Diet and Nutrition Survey (NDNS) rolling programme. The NDNS rolling programme is a nationally representative survey of food consumption, nutrient intakes and nutritional status of people aged 1.5 years and over living in England, Wales, Scotland and Northern Ireland. The study population comprised survey members who completed three or four days of dietary recording and who provided a blood sample. After excluding survey members with selfreported diabetes (n=25), there were 1016 results for HbA1c and 942 for glucose (not the same individuals in each case). Around 5.4% of men and 1.7% of women aged 19-64 years, and 5.1% of men and 5.9% of women aged ≥65 years had impaired fasting glucose (glucose concentrations 6.1-6.9 mmol/L). Over 20% of men aged ≥65 years had fasting glucose concentrations above the clinical cut-off for diabetes (?7 mmol/L) compared to 2.1% of women of similar age ( p=0.007). Similarly, 16.4% of men had HbA1c concentrations ≥6.5%, compared to 1.5% of women (p=0.003). Children and teenagers had fasting glucose and HbA1c values largely within the normal range. To conclude, this is the first study to provide data on the distribution of HbA1c and glucose concentrations in a nationally representative sample of the British population. The high prevalence of men aged ≥65 years with HbA1cand glucose concentrations above the clinical cut-off of diabetes warrants further attention. [ABSTRACT FROM AUTHOR]

Background: Idiopathic Generalized Epilepsies (IGE) are a subset of syndromes defined by the International League against Epilepsy (ILAE) with the particularity to respond to a narrow number of ASMs and particularly to valproic acid (VPA). Recommendations have changed in the last decade. We aimed to describe changes in antiseizure medication (ASM) in adult IGE over the last 10 years., Methods: Cross-sectional study comparing two cohorts of patients ≥ 16 years receiving ASM for IGE in a tertiary center (year 2013 and 2023). We collected clinical-demographic variables and ASM, analysing diagnosis and ASM prescription., Results: 249 patients were included in 2013 (53.8 % women; mean age 35.6 years ±14.6 standard deviation [SD]) and 278 in 2023 (61.2 % women, mean age 38.1 years ±16.1 SD). In 2023, the most frequent IGE subtype syndrome was juvenile myoclonic epilepsy (JME) (39.6 % vs 33.3 % in 2013), followed by epilepsy with generalized tonic-clonic seizures alone (28.4 % vs 42.6 %). Valproic acid (VPA) was the most used ASM in both periods, although it was prescribed less frequently in 2023 compared to 2013 (49.3 % vs. 69.1 %; p < 0.001). Lamotrigine (LTG) was the second most used ASM in 2013 (14.1 %), followed by levetiracetam (LEV) (12.4 %). By contrast, in 2023 LEV was the second most used ASM (29.5 %), followed by LTG (21.6 %) (LEV p < 0.001; LTG p = 0.025). VPA use decreased in women under 45 years (57.9 % vs 20.3 %, p < 0.001), with a subsequent increase of LEV (19.6 % vs 45.8 %, p < 0.001). In men we observed no significant differences in the use of VPA (80.0 % vs 75.9 %, p = 0.463)., Conclusions: The use of VPA has decreased during the last decade for all IGEs and particularly in women of childbearing potential, along with an increase in the use of LEV and LTG., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [I. Elosua-Bayés has no conflicts of interest. L. Abraira has received research funding and speaking fees from UCB Pharma, BIAL Pharmaceutical, Jazz Pharmaceuticals, EISAI Inc, Neuraxpharm, Exeltis, Angelini Pharma and Esteve Laboratorios. E. Fonseca has received funding and speaker fees from UCB Pharma, BIAL Pharmaceutical, Jazz Pharmaceuticals, EISAI Inc, Neuraxpharm, Sanofi Genzyme, Angelini Pharma and Esteve Laboratorios. M. Toledo has received research funding and speaking fees from UCB Pharma, Angelini, Arvelle, Jazz Pharma, BIAL Pharmaceutical, EISAI Inc, and Esteve Laboratorios. E. Santamarina has received research funding and speaking fees from UCB Pharma, BIAL Pharmaceutical, EISAI Inc, and Esteve Laboratorios. D. Campos has received travel support from UCB Pharma, BIAL Pharmaceutical, Jazz Pharmaceuticals and Angelini Pharma S. Lallana has received travel support from UCB Pharma, BIAL Pharmaceutical, Jazz Pharmaceuticals and Angelini Pharma. The remaining authors have no conflicts of interest in relation to this research paper. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines]., (Copyright © 2024 Elsevier Inc. All rights reserved.)

Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period through a case series and literature review., Methods: Six migraine-diagnosed women received CGRP-mAbs; treatment ceased upon pregnancy. We collected data and conducted safety assessments. To provide a comprehensive context, we performed a literature review., Results: The series includes three erenumab, two fremanezumab and one galcanezumab case. A fremanezumab recipient experienced miscarriage; severe perinatal asphyxia linked to dystocia occurred with erenumab (140 mg). Database reviews revealed 63 spontaneous abortions, eight premature births, and seven birth defects among 286 World Health Organization and 65 European Medicines Agency cases. These rates align with untreated population rates., Conclusions: CGRP-mAbs use in the periconceptional period does not lead to clinically significant increase in pregnancy-related pathology or adverse effects on newborns within our case series and the literature reviewed., Competing Interests: Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: IEB and LM report no disclosures. AA has received honoraria from Allergan-Abbvie, Novartis, and Lilly. EC has received honoraria as a speaker for Chiesi and Novartis. MTF has received honoraria as a consultant or speaker for Allergan-Abbvie, Almirall, Chiesi, Eli Lilly, Novartis and Teva. PP-R has received honoraria as a consultant and speaker for Abbvie, Almirall, Amgen, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis and Teva. Her research group has received research grants from Allergan, Novartis and Teva, and has received funding for clinical trials from Alder, Abbvie, Amgen, Electrocore, Eli Lilly, Lundbeck, Novartis and Teva. She is the Honorary Secretary of the International Headache Society. She is on the editorial board of Revista de Neurologia, and an associate editor for Cephalalgia, Headache, Neurologia, Frontiers of Neurology and The Journal of Headache and Pain. She is a member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of www.midolordecabeza.org. PP-R does not own stocks in any pharmaceutical company.

Background: Approximately 30% of patients presenting with acute ischemic stroke (AIS) due to large vessel occlusion have pre-stroke modified Rankin Scale (mRS) scores ≥2. We aimed to investigate the safety and outcomes of endovascular treatment (EVT) in patients with AIS with moderate pre-stroke disability (mRS score 3) in an extended time frame (ie, 6-24 hours from the last time known well)., Methods: Data were collected from five centers in Europe and the USA from January 2018 to January 2023 and included 180 patients who underwent EVT in an extended time frame. Patients were divided into two groups of 90 each (Group 1: pre-mRS 0-2; Group 2: pre-mRS 3; 71% women, mean age 80.3±11.9 years). Primary outcomes were: (1) 3-month good clinical outcome (Group 1: mRS 0-2, Group 2: mRS 0-3) and ΔmRS; (2) any hemorrhagic transformation (HT); and (3) symptomatic HT. Secondary outcomes were successful and complete recanalization after EVT and 3-month mortality., Results: No between-group differences were found in the 3-month good clinical outcome (26.6% vs 25.5%, P=0.974), any HT (26.6% vs 22%, P=0.733), and symptomatic HT (8.9 vs 4.4%, P=0.232). Unexpectedly, ΔmRS was significantly smaller in Group 2 compared with Group 1 (1.64±1.61 vs 2.97±1.69, P<0.001). No between-group differences were found in secondary outcomes., Conclusion: Patients with pre-stroke mRS 3 are likely to have similar outcomes after EVT in the extended time frame to those with pre-stroke mRS 0-2, with no difference in safety., Competing Interests: Competing interests: T.N. Nguyen discloses advisory board for Brainomix, Aruna Bio; Associate Editor of Stroke. The other authors declare that they have no conflict of interests., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)

Introduction: The screening for atrial fibrillation (AF) scale (SAFE score) was recently developed to provide a prediction of the diagnosis of AF after an ischemic stroke. It includes 7 items: age ≥ 65 years, bronchopathy, thyroid disease, cortical location of stroke, intracranial large vessel occlusion, NT-ProBNP ≥250 pg/mL, and left atrial enlargement. In the internal validation, a good performance was obtained, with an AUC = 0.88 (95% CI 0.84-0.91) and sensitivity and specificity of 83% and 80%, respectively, for scores ≥ 5. The aim of this study is the external validation of the SAFE score in a multicenter cohort., Methods: A retrospective multicenter study, including consecutive patients with ischemic stroke or transient ischemic attack between 2020 and 2022 with at least 24 hours of cardiac monitoring. Patients with previous AF or AF diagnosed on admission ECG were excluded., Results: Overall, 395 patients were recruited for analysis. The SAFE score obtained an AUC = 0.822 (95% CI 0.778-0.866) with a sensitivity of 87.2%, a specificity of 65.4%, a positive predictive value of 44.1%, and a negative predictive value of 94.3% for a SAFE score ≥ 5, with no significant gender differences. Calibration analysis in the external cohort showed an absence of significant differences between the observed values and those predicted by the model (Hosmer-Lemeshow's test 0.089)., Conclusions: The SAFE score showed adequate discriminative ability and calibration, so its external validation is justified. Further validations in other external cohorts or specific subpopulations of stroke patients might be required., Competing Interests: The group of authors of the Torrecardenas University Hospital who proposed the present work (MQL, LAP, JGT, AAP, and PMS) overlaps with those who developed the SAFE score. However, these authors have deliberately avoided participating in the statistical analysis of the results, focusing instead on the design of the study, data collection, and drafting of the manuscript., (Copyright © 2023 Miguel Quesada López et al.)

The ATHLOS cohort is composed of several harmonized datasets of international groups related to health and aging. As a result, the Healthy Aging index has been constructed based on a selection of variables from 16 individual studies. In this paper, we consider additional variables found in ATHLOS and investigate their utilization for predicting the Healthy Aging index. For this purpose, motivated by the volume and diversity of the dataset, we focus our attention upon data clustering, where unsupervised learning is utilized to enhance prediction power. Thus we show the predictive utility of exploiting hidden data structures. In addition, we demonstrate that imposed computation bottlenecks can be surpassed when using appropriate hierarchical clustering, within a clustering for ensemble classification scheme, while retaining prediction benefits. We propose a complete methodology that is evaluated against baseline methods and the original concept. The results are very encouraging suggesting further developments in this direction along with applications in tasks with similar characteristics. A straightforward open source implementation for the R project is also provided (https://github.com/Petros-Barmpas/HCEP)., Supplementary Information: The online version contains supplementary material available at 10.1007/s13755-022-00171-1., (© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022.)